Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

ABCLBullishAnalyst Target Updateanalyst

Medium materiality6/10

Jefferies initiates AbCellera Biologics at Buy with $21 target

Oct 30, 2026, 1:27 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The Buy initiation and substantial stated target premium support a bullish view, though the target is an analyst estimate and no supporting thesis is provided.

AI summary

What happened, with direct paths to the underlying reporting

Jefferies initiated coverage of ABCL at Buy with a $21 target, about 76% above the reported $11.94 price. This is a bullish analyst opinion, not a guaranteed return.

Jefferies starts ABCL at Buy.
$21 target versus $11.94 posted price.

Key facts

01
Target: $21
02
Posted price: $11.94
03
Analyst firm: Jefferies
04
Analyst: Roger Song

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Jefferies initiates AbCellera Biologics at Buy with $21 target

Key facts

AbCellera launches $200M equity offering to fund ABCL635 and pipeline

AbCellera menopause trial results trigger near-term ABCL stock rally

Jazz-AbCellera pact signals platform validation and potential ABCL revenue milestones